FDA approves Shionogi's thrombocytopenia drug

FDA approved Mulpleta lusutrombopag from Shionogi & Co. Ltd. (Tokyo:4507) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

Mulpleta is the second drug to receive FDA approval in the indication following Doptelet avatrombopag from the AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) in May. Both drugs are oral thrombopoietin (TPO) receptor (CD110; Mpl) agonists (see “Dova’s Thrombocytopenia Drug Wins FDA Approval”)...